 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| BPI-452080 / Betta Pharma
New P1 trial: A Study of BPI-452080 in Subjects With Solid Tumors (clinicaltrials.gov) - May 6, 2023
P1, N=87, Not yet recruiting, Sponsor: Betta Pharmaceuticals Co., Ltd.
- BPI-452080 / Betta Pharma
BPI-452080: A potent and selective HIF-2? inhibitor for the treatment of clear cell renal cell carcinoma, von Hippel-Lindau disease, and other solid tumors (Section 17; Poster Board #25) - Mar 14, 2023 - Abstract #AACR2023AACR_2553;
inhibitor which presents a novel therapeutic option for ccRCC, von Hippel-Lindau disease, and other solid tumors. BPI-452080 is planned to enter Phase I clinical trial in China in early 2023.